CA2351522A1 - Acides nucleiques et polypeptides et utilisations correspondantes - Google Patents

Acides nucleiques et polypeptides et utilisations correspondantes Download PDF

Info

Publication number
CA2351522A1
CA2351522A1 CA002351522A CA2351522A CA2351522A1 CA 2351522 A1 CA2351522 A1 CA 2351522A1 CA 002351522 A CA002351522 A CA 002351522A CA 2351522 A CA2351522 A CA 2351522A CA 2351522 A1 CA2351522 A1 CA 2351522A1
Authority
CA
Canada
Prior art keywords
polypeptide
nucleic acid
seq
elvis
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002351522A
Other languages
English (en)
Inventor
Samantha Busfield
David P. Gearing
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2351522A1 publication Critical patent/CA2351522A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des molécules d'acide nucléique isolées, désignées sous les noms de ELVIS-1, ELVIS-2 et ELVIS-3 (Variante du type facteur de croissance épidermique dans la peau 1, 2 et 3). Les molécules d'acide nucléique ELVIS codent pour des protéines complètement sécrétées et transmembranaires présentant une homologie avec EGF and TGF-.alpha.. L'invention concerne également des molécules d'acide nucléique antisens, des vecteurs d'expression contenant les molécules d'acide nucléique selon l'invention, des cellules hôtes dans lesquelles ont été introduits les vecteurs d'expression ainsi que des animaux transgéniques dans lesquels une molécule d'acide nucléique selon l'invention a été introduite ou disloquée. L'invention concerne en outre des polypeptides isolés, des polypeptides de fusion, des anticorps et des peptides antigéniques. Par ailleurs, l'invention concerne des méthodes de diagnostic, des méthodes de criblage ainsi que des méthodes thérapeutiques utilisant les compositions selon l'invention. Les acides nucléiques et les polypeptides selon l'invention sont utiles en tant qu'agents de modulation et servent à réguler plusieurs processus cellulaires. Par conséquent, dans un aspect, l'invention concerne des molécules d'acide nucléique isolées codant pour un polypeptide selon l'invention ou une partie biologiquement active de celui-ci. L'invention concerne enfin des molécules d'acide nucléique qui sont utiles en tant qu'amorces ou en tant que sondes d'hybridation pour la détection d'acides nucléiques codant pour un polypeptide selon l'invention.
CA002351522A 1998-11-19 1999-11-19 Acides nucleiques et polypeptides et utilisations correspondantes Abandoned CA2351522A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19626998A 1998-11-19 1998-11-19
US09/196,269 1998-11-19
PCT/US1999/027576 WO2000029438A1 (fr) 1998-11-19 1999-11-19 Acides nucleiques et polypeptides et utilisations correspondantes

Publications (1)

Publication Number Publication Date
CA2351522A1 true CA2351522A1 (fr) 2000-05-25

Family

ID=22724690

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002351522A Abandoned CA2351522A1 (fr) 1998-11-19 1999-11-19 Acides nucleiques et polypeptides et utilisations correspondantes

Country Status (5)

Country Link
EP (1) EP1131350A4 (fr)
JP (1) JP2002530064A (fr)
AU (1) AU2153500A (fr)
CA (1) CA2351522A1 (fr)
WO (1) WO2000029438A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ507728A (en) * 1998-04-29 2002-06-28 Genesis Res & Dev Corp Ltd Information from a cDNA library created from keratinocytes, dermal papilla, neonatal foreskin fibroblast or embryonic skin cells is used to treating cancer, angiogenesis, skin inflammation, inflammatory diseases or stimulating keratinocyte growth
US6573095B1 (en) 1998-04-29 2003-06-03 Genesis Research & Development Corporation Limited Polynucleotides isolated from skin cells
JP2004502405A (ja) * 2000-01-25 2004-01-29 ハイセック，インコーポレーテッド トランスフォ−ミング成長因子アルファｔｇｆアルファ様ポリペプチドおよびポリヌクレオチドに関する方法と材料
WO2001090357A1 (fr) * 2000-05-24 2001-11-29 Genesis Research & Development Corporation Limited Compositions isolees des cellules cutanees et methodes d'utilisation de ces compositions
CN1486204A (zh) 2001-01-12 2004-03-31 ������˹ҩƷ��˾ 用于胰岛再生的含胃泌素/cck受体配基及egf受体配基的组合物
US7157558B2 (en) * 2001-06-01 2007-01-02 Genentech, Inc. Polypeptide encoded by a polynucleotide overexpresses in tumors
US7037504B2 (en) 2001-10-23 2006-05-02 Waratah Pharmaceuticals, Inc. Epidermal growth factor protein and gene, and methods of use therefor
EP1837031B1 (fr) 2002-06-07 2009-10-14 Waratah Pharmaceuticals, Inc. Methodes et compositions pour le traitement du diabete
DE60326002D1 (de) 2002-10-22 2009-03-12 Waratah Pharmaceuticals Inc Behandlung von diabetes.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633147A (en) * 1994-03-08 1997-05-27 Human Genome Sciences, Inc. Transforming growth factor αH1
CA2250268A1 (fr) * 1996-04-10 1997-10-16 Human Genome Sciences, Inc. Facteur de croissance extracellulaire/epidermique hcaba58x
US6074841A (en) * 1996-08-19 2000-06-13 Millennium Biotherapeutics, Inc. Don-1 gene and polypeptides and uses therefor
US5892012A (en) * 1997-08-21 1999-04-06 Hillman; Jennifer L. Rab Proteins
NZ507728A (en) * 1998-04-29 2002-06-28 Genesis Res & Dev Corp Ltd Information from a cDNA library created from keratinocytes, dermal papilla, neonatal foreskin fibroblast or embryonic skin cells is used to treating cancer, angiogenesis, skin inflammation, inflammatory diseases or stimulating keratinocyte growth

Also Published As

Publication number Publication date
EP1131350A1 (fr) 2001-09-12
JP2002530064A (ja) 2002-09-17
EP1131350A4 (fr) 2005-05-04
AU2153500A (en) 2000-06-05
WO2000029438A9 (fr) 2001-01-04
WO2000029438A1 (fr) 2000-05-25

Similar Documents

Publication Publication Date Title
US20050014241A1 (en) Human glucose-6-phosphatase molecules and uses thereof
EP1141008A1 (fr) Proteines ressemblant au recepteur de la cytokine de classe ii, et acides nucleiques les codant
EP1710299A2 (fr) Proteines secretées et polynucleotides codant pour ces proteines
WO2001010902A2 (fr) Polynucleotides et polypeptides codes par ces derniers
WO2000039149A2 (fr) Proteines secretees et leurs utilisations
CA2351522A1 (fr) Acides nucleiques et polypeptides et utilisations correspondantes
US7803564B2 (en) EGF-like nucleic acids and polypeptides and uses thereof
AU779667B2 (en) Polynucleotides and polypeptides encoded thereby
WO2000018904A9 (fr) Proteines secretees et acides nucleiques les codant
US6406884B1 (en) Secreted proteins and uses thereof
US20050032172A1 (en) Novel molecules of the FTHMA-070-related protein family and the T85-related protein family and uses thereof
US6872811B1 (en) HRPCa9 and HRPCa10 nucleic acids and polypeptides
US6380382B1 (en) Gene encoding a protein having diagnostic, preventive, therapeutic, and other uses
CA2325359A1 (fr) Molecules d'acide nucleique et de proteine lrsg et leurs utilisations
WO2000018800A1 (fr) Nouvelles proteines secretees immunomodulatrices et leurs applications
EP1444260A4 (fr) Proteines secretees et leur utilisation
WO2001005971A9 (fr) Polypeptides et polynucleotides les codant
WO2000032746A2 (fr) Acides nucleiques et polypeptides netrinoïdes et ependyminoïdes et leurs utilisations
WO2001000878A2 (fr) Nouveau membre de la famille des facteurs de croissance des cellules endotheliales vasculaires et son utilisation
US20020076700A1 (en) Novel polypeptides and nucleic acids encoding same
US20030022286A1 (en) Novel transporter-like genes and uses therefor
US20020164689A1 (en) Class II cytokine receptor-like proteins and nucleic acids encoding them
EP1586660A1 (fr) Nouvelles molécules de la famille des protéines liées à T85 et utilisation des dites molécules
US20030198958A1 (en) Noval human proteins, polynucleotides encoding them and methods of using the same
WO2001000644A1 (fr) Nouveaux genes codant pour des proteines s'utilisant a des fins de diagnostic, preventives, therapeutiques et autres

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20031119